Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sitagliptin/Metformin ER Tablets in Healthy Subjects
NCT07763964Completed
- Sponsor
- Adium Pharma
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Adium Pharma. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Started Dec 2025; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07763964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07763964.